Ligand-induced changes in 2-aminopurine fluorescence as a probe for small molecule binding to HIV-1 TAR RNA

RNA

Volumn 10, Issue 9, 2004, Pages 1459-1468

  Bradrick, Thomas D ^a   Marino, John P ^a  

^a NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

Author keywords

2 AP; Conformation; Fluorescence; HIV 1; RNA; TAR

Indexed keywords

2 AMINOPURINE; ANTIVIRUS AGENT; ARGININAMIDE; ARGININE DERIVATIVE; LIGAND; NEOMYCIN; PROTEIN INHIBITOR; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

ACCURACY; ARTICLE; BINDING AFFINITY; BINDING SITE; DRUG PROTEIN BINDING; DRUG TARGETING; FLUORESCENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR PROBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; STEADY STATE; VIRUS GENOME; VIRUS REPLICATION;

2-AMINOPURINE; ARGININE; BINDING SITES; BINDING, COMPETITIVE; FLUORESCENCE; GENE PRODUCTS, TAT; HIV-1; HUMANS; LIGANDS; NEOMYCIN; NUCLEIC ACID CONFORMATION; PEPTIDE FRAGMENTS; RNA, VIRAL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 4344579386     PISSN: 13558382     EISSN: None     Source Type: Journal    
DOI: 10.1261/rna.7620304     Document Type: Article

References (48)

1. Aboulela, F., Karn, J., and Varani, G. 1995. The structure of the Human-Immunodeficiency-Virus Type-1 TAR RNA reveals principles of RNA recognition by Tat protein. J. Mol. Biol. 253: 313-332.
2. Arzumanov, A., Godde, F., Moreau, S., Toulme, J.J., Weeds, A., and Gait, M.J. 2000. Use of the fluorescent nucleoside analogue benzo[g]quinazoline 2′-O-methyl-beta-D-ribofuranoside to monitor the binding of the HIV-1 Tat protein or of antisense oligonucleotides to the TAR RNA stem-loop. Helv. Chim. Acta 83: 1424-1436.
3. Arzumanov, A., Walsh, A.P., Liu, X.H., Rajwanshi, V.K., Wengel, J., and Gait, M.J. 2001. Oligonucleotide analogue interference with the HIV-1 Tat protein-TAR RNA interaction. Nucleosides Nucleotides & Nucleic Acids 20: 471-480.
4. Austin, R.J., Xia, T.B., Ren, J.S., Takahashi, T.T., and Roberts, R.W. 2003. Differential modes of recognition in N peptide-boxB complexes. Biochemistry 42: 14957-14967.
5. Barrick, J.E. and Roberts, R.W. 2003. Achieving specificity in selected and wild-type N peptide-RNA complexes: The importance of discrimination against noncognate RNA targets. Biochemistry 42: 12998-13007.
6. Blount, K.F. and Tor, Y. 2003. Using pyrene-labeled HIV-1 TAR to measure RNA-small molecule binding. Nucleic Acids Res. 31: 5490-5500.
7. Calnan, B.J., Biancalana, S., Hudson, D., and Frankel, A.D. 1991a. Analysis of arginine-rich peptides from the HIV Tat Protein reveals unusual features of RNA protein recognition. Genes & Dev. 5: 201-210.
8. Calnan, B.J., Tidor, B., Biancalana, S., Hudson, D., and Frankel, A.D. 1991b. Arginine-mediated RNA recognition-the arginine fork. Science 252: 1167-1171.
9. Churcher, M.J., Lamont, C., Hamy, F., Dingwall, C., Green, S.M., Lowe, A.D., Butler, P.J.G., Gait, M.J., and Karn, J. 1993. High-affinity binding of TAR RNA by the Human-Immunodeficiency-Virus Type-1 Tat protein requires base-pairs in the RNA stem and amino acid residues flanking the basic region. J. Mol. Biol. 230: 90-110.
10. Davis, B., Afshar, M., Varani, G., Murchie, A.I.H., Karn, J., Lentzen, G., Drysdale, M., Bower, J., Potter, A.J., Starkey, I.D., et al. 2004. Rational design of inhibitors of HIV-1 TAR RNA through the stabilisation of electrostatic "hot spots". J. Mol. Biol. 336: 343-356.
11. Dejong, E.S., Chang, C.-e., Gilson, M.K., and Marino, J.P. 2003. Proflavine acts as a Rev inhibitor by targeting the high-affinity Rev binding site of the Rev responsive element of HIV-1. Biochemistry 42: 8035-8046.
12. Dinesh, C.U. and Rana, T.M. 2003. Inhibitors of the Tat-TAR interactions. In Small molecule DNA and RNA binders (eds. M. Demeunynck et al.), pp. 58-87. Wiley-VCH, Darmstadt, Germany.
13. Du, Z.H., Lind, K.E., and James, T.L. 2002. Structure of TAR RNA complexed with a Tat-TAR interaction nanomolar inhibitor that was identified by computational screening. Chem. Biol. 9: 707-712.
14. Faber, C., Sticht, H., Schweimer, K., and Rosch, P. 2000. Structural rearrangements of HIV-1 Tat-responsive RNA upon binding of neomycin B. J. Biol. Chem. 275: 20660-20666.
15. Gelus, N., Hamy, F., and Bailly, C. 1999. Molecular basis of HIV-1 TAR RNA specific recognition by an acridine tat-antagonist. Bioorg. Med. Chem. 7: 1075-1079.
16. Hamy, F., Felder, E.R., Heizmann, G., Lazdins, J., AboulEla, F., Varani, G., Karn, J., and Klimkait, T. 1997. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc. Natl. Acad. Sci. 94: 3548-3553.
17. Hamy, F., Brondani, V., Florsheimer, A., Stark, W., Blommers, M.J.J., and Klimkait, T. 1998. A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition. Biochemistry 37: 5086-5095.
18. Harrich, D., Ulich, C., and Gaynor, R.B. 1996. A critical role for the TAR element in promoting efficient human immunodeficiency virus type 1 reverse transcription. J. Virol. 70: 4017-4027.
19. Harrich, D., Ulich, C., GarciaMartinez, L.F., and Gaynor, R.B. 1997. Tat is required for efficient HIV-1 reverse transcription. EMBO J. 16: 1224-1235.
20. Harris, D.A., Rueda, D., and Walter, N.G. 2002. Local conformational changes in the catalytic core of the trans-acting hepatitis delta virus ribozyme accompany catalysis. Biochemistry 41: 12051-12061.
21. Hwang, S., Tamilarasu, N., Kibler, K., Cao, H., Ali, A., Ping, Y.H., Jeang, K.T., and Rana, T.M. 2003. Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication. J. Biol. Chem. 278: 39092-39103.
22. Jeong, S., Sefcikova, J., Tinsley, R.A., Rueda, D., and Walter, N.G. 2003. Trans-acting hepatitis delta virus ribozyme: Catalytic core and global structure are dependent on the 5′ substrate sequence. Biochemistry 42: 7727-7740.
23. Kaul, M., Barbieri, C.M., and Pilch, D.S. 2004. Fluorescence-based approach for detecting and characterizing antibiotic-induced conformational changes in ribosomal RNA: Comparing aminoglycoside binding to prokaryotic and eukaryotic ribosomal RNA sequences. J. Am. Chem. Soc. 126: 3447-3453.
24. Kirk, S.R., Luedtke, N.W., and Tor, Y. 2001. 2-aminopurine as a real-time probe of enzymatic cleavage and inhibition of hammer-head ribozymes. Bioorg. Med. Chem. 9: 2295-2301.
25. Lacourciere, K.A., Stivers, J.T., and Marino, J.P. 2000. Mechanism of Neomycin and Rev peptide binding to the Rev responsive element of HIV-1 as determined by fluorescence and NMR spectroscopy. Biochemistry 39: 5630-5641.
26. Lind, K.E., Du, Z.H., Fujinaga, K., Peterlin, B.M., and James, T.L. 2002. Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA. Chem. Biol. 9: 185-193.
27. Litovchick, A., Lapidot, A., Eisenstein, M., Kalinkovich, A., and Borkow, G. 2001. Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: Synthesis and anti-HIV activities. Biochemistry 40: 15612-15623.
28. Long, K.S. and Crothers, D.M. 1999. Characterization of the solution conformations of unbound and Tat peptide-bound forms of HIV-1 TAR RNA. Biochemistry 38: 10059-10069.
29. Mayhood, T., Kaushik, N., Pandey, P.K., Kashanchi, F., Deng, L.W., and Pandey, V.N. 2000. Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element. Biochemistry 39: 11532-11539.
30. Mei, H.Y., Galan, A.A., Halim, N.S., Mack, D.P., Moreland, D.W., Sanders, K.B., Truong, H.N., and Czarnik, A.W. 1995. Inhibition of an HIV-1 Tat-derived peptide binding to TAR RNA by amino-glycoside antibiotics. Bioorg. Med. Chem. Letts. 5: 2755-2760.
31. Mei, H.Y., Mack, D.P., Galan, A.A., Halim, N.S., Heldsinger, A., Loo, J.A., Moreland, D.W., Sannes-Lowery, K.A., Sharmeen, L., Truong, H.N., et al. 1997. Discovery of selective, small-molecule inhibitors of RNA complexes 1. The Tat protein TAR RNA complexes required for HIV-1 transcription. Bioorg. Med. Chem. 5: 1173-1184.
32. Mei, H.Y., Cui, M., Heldsinger, A., Lemrow, S.M., Loo, J.A., Sannes-Lowery, K.A., Sharmeen, L., and Czarnik, A.W. 1998. Inhibitors of protein-RNA complexation that target the RNA: Specific recognition of human immunodeficiency virus type 1 TAR RNA by small organic molecules. Biochemistry 37: 14204-14212.
33. Mestre, B., Arzumanov, A., Singh, M., Boulme, F., Litvak, S., and Gait, M.J. 1999. Oligonucleotide inhibition of the interaction of HIV-1 Tat protein with the trans-activation responsive region (TAR) of HIV RNA. Biochim. Biophys. Acta 1445: 86-98.
34. Murchie, A.I H., Davis, B., Isel, C., Afshar, M., Drysdale, M.J., Bower, J., Potter, A.J., Starkey, I.D., Swarbrick, T.M., Mirza, S., et al. 2004. Structure-based drug design targeting an inactive RNA conformation: Exploiting the flexibility of HIV-1 TAR RNA. J. Mol. Biol. 336: 625-638.
35. Ptak, R.G. 2002. HIV-1 regulatory proteins: Targets for novel drug development. Expert Opin. Investigat. Drugs 11: 1099-1115.
36. Puglisi, J.D., Tan, R., Calnan, B.J., Frankel, A.D., and Williamson, J.R. 1992. Conformation of the TAR RNA-arginine complex by NMR spectroscopy. Science 257: 76-80.
37. Rist, M. and Marino, J.P. 2001. Fluorescent nucleotide base analogs as probes of nucleic acid structure, dynamics and interactions. Curr. Org. Chem. 6: 775-793.
38. -. 2002. Mechanism of nucleocapsid protein catalyzed structural isomerization of the dimerization initiation site of HIV-1. Biochemistry 41: 14762-14770.
39. Sannes-Lowery, K.A., Mei, H.Y., and Loo, J.A. 1999. Studying aminoglycoside antibiotic binding to HIV-1 TAR RNA by electrospray ionization mass spectrometry. Int. J. Mass Spect. 193: 115-122.
40. Scopes, R.K. 1974. Measurement of protein by spectrophotometry at 205 nm. Anal. Biochem. 59: 277-282.
41. Sucheck, S.J. and Wong, C.H. 2000. RNA as a target for small molecules. Curr. Opin. Chem. Biol. 4: 678-686.
42. Tamilarasu, N., Huq, I., and Rana, T.M. 2000. Design, synthesis, and biological activity of a cyclic peptide: An inhibitor of HIV-1 Tat-TAR interactions in human cells. Bioorg. Med. Chem. Letts. 10: 971-974.
43. Tao, J.S. and Frankel, A.D. 1992. Specific binding of arginine to TAR RNA. Proc. Natl. Acad. Sci. 89: 2723-2726.
44. Tor, Y. 2003. Targeting RNA with small molecules. Chembiochem 4: 998-1007.
45. Wang, S., Huber, P.W., Cui, M., Czarnik, A.W., and Mei, H.Y. 1998. Binding of neomycin to the TAR element of HIV-1 RNA induces dissociation of Tat protein by an allosteric mechanism. Biochemistry 37: 5549-5557.
46. Weeks, K.M. and Crothers, D.M. 1991. RNA recognition by Tat-derived peptides: Interaction in the major groove? Cell 66: 577-588.
47. -. 1992. RNA binding assays for Tat-derived peptides: Implications for specificity. Biochemistry 31: 10281-10287.
48. Weeks, K.M., Ampe, C., Schultz, S.C., Steitz, T.A., and Crothers, D.M. 1990. Fragments of the HIV-1 Tat protein specifically bind TAR RNA. Science 249: 1281-1285.